# LivaNova PLC (LIVN) Stock Analysis: Exploring a 33.89% Potential Upside and Analyst Consensus

- Link: https://www.directorstalkinterviews.com/livanova-plc-livn-stock-analysis-exploring-a-33-89-potential-upside-and-analyst-consensus/4121206495
- Published: 2025-07-08T10:44:26+01:00
- Author: Madison Wilson

LivaNova PLC (NASDAQ: LIVN), a key player in the medical devices industry, has been
capturing the attention of investors with its promising growth prospects and significant
potential upside. Headquartered in London, this healthcare company specializes in
pioneering technologies for neurological and cardiac conditions. Operating in the
Cardiopulmonary and Neuromodulation segments, LivaNova is committed to enhancing
patient care through advanced medical solutions.

As of the latest trading data, LivaNova’s stock is priced at $45.58, reflecting 
a slight decline of 0.01% from its previous close. The stock has fluctuated between
$33.85 and $54.59 over the past year, indicating a moderate volatility that may 
interest risk-tolerant investors. One of the most compelling figures for potential
investors is the average analyst target price of $61.03, which suggests a potential
upside of 33.89% from the current price levels.

Despite the absence of a trailing P/E ratio due to its current earnings performance,
LivaNova’s forward P/E ratio stands at a promising 11.57. This suggests that analysts
expect an improvement in earnings, a sentiment echoed by the company’s healthy revenue
growth of 7.40%. However, the company reported an earnings per share (EPS) of -4.07
and a negative return on equity of -19.70%, reflecting ongoing challenges that it
must navigate to achieve profitability.

The absence of dividends indicates that LivaNova is currently reinvesting its earnings
to drive growth and innovation, which aligns with its strategic focus in cutting-
edge medical technologies. The analyst ratings add further depth to the investment
narrative, with 8 buy ratings and 3 hold ratings, and no sell ratings, illustrating
confidence in the company’s long-term potential.

LivaNova’s technical indicators provide additional insights for investors. The stock
is currently trading slightly below its 200-day moving average of $46.15 but above
its 50-day moving average of $43.38. The relative strength index (RSI) of 57.86 
suggests that the stock is neither overbought nor oversold, which may present a 
buying opportunity for those seeking entry at a relatively neutral point. The MACD
indicator at 0.62, slightly below the signal line of 0.78, points to a cautious 
optimism among traders.

The company’s robust free cash flow of approximately $782 million underscores its
financial stability and capacity to fund its strategic initiatives. This liquidity
is vital as LivaNova continues investing in its product pipeline and market expansion
efforts.

LivaNova PLC’s strategic positioning in the healthcare sector, coupled with its 
innovative product offerings, has positioned it as a formidable player in the medical
devices market. For investors seeking exposure to the healthcare industry with a
focus on growth and innovation, LivaNova presents a compelling case. The potential
upside, coupled with strong analyst consensus and strategic financial management,
makes LivaNova a stock worth considering for a diversified investment portfolio.

Share on: